Ran Nusbaum is listed as a director on 2 SEC Form D filings by 1 issuer between Feb 2014 and Apr 2016: BIO BLAST PHARMA LTD. (New Haven, CT — pharmaceuticals — 2014–2016; $6.7M reported sold to 28 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Dalia Megiddo (2 shared filings), Fredric D. Price (2 shared filings), Marlene Haffner (2 shared filings), Udi Gilboa (2 shared filings), Colin Foster (1 shared filing) and 10 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Ran. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Ran Nusbaum and found 3 differences: Reported revenue range changed between filings; Address moved from Tel Aviv, Israel (as filed: L3) to New Haven, CT; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.